Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

ASCO 2024

31 May - 4 Jun 2024

Published: 13 Jun 2024

Views: 47

Rating:

Save

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Dr Giuseppe Curigliano speaks to ecancer at ASCO 2024 about results from DESTINY-Breast06 - a study evaluating trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with hormone receptor-positive (HR positive), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy.

The 866 participants were randomly assigned to receive either trastuzumab deruxtecan or a chemotherapy of their doctor’s choice.

For those with HER2-low cancer, the median progression-free survival was 13.2 months for those who received trastuzumab deruxtecan versus 8.1 months for those who received chemotherapy.

Related Videos

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

Post neoadjuvant management in BRCA mutant breast cancer patients

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

More from ecancer